MaxCyte Q2 revenue beats estimates

MaxCyte

12/08/2026 21:20

Overview
US cell engineering platform's Q2 revenue fell 15% yr/yr but beat analyst expectations
Q2 adjusted EBITDA loss was larger than analyst consensus
Company repurchased $5.5 mln in stock and announced Genentech partnership post-quarter

Outlook
MaxCyte sees 2026 revenue at $30 mln to $32 mln
Company expects 2026 core revenue of $25 mln to $27 mln
MaxCyte expects to end 2026 with at least $130.5 mln in cash, equivalents and investments

Result Drivers
INSTRUMENT PLACEMENTS - Co said execution on instrument placements supported Q2 results
SPL PROGRAM REVENUE - SPL Program-related revenue rose, driven by growing commercial royalty revenue and advancement of SPL programs through the clinic
OPERATING EXPENSES - Lower operating expenses contributed to reduced net loss in Q2

Company press release: ID:nGNX7Tg8w2

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$7.30 mln
$6.48 mln (5 Analysts)
Q2 Net Loss
 
$8.90 mln
 
Q2 Adjusted EBITDA
Miss
-$9.30 mln
-$8.93 mln (4 Analysts)
Q2 Cash & Investments
 
$141.90 mln
 
Q2 Gross Profit
 
$5.60 mln
 
Q2 Operating Expenses
 
$15.80 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for MaxCyte Inc is $4.50, about 262.9% above its August 11 closing price of $1.24

Reuters Recommended Reads
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise
Aug 11 - Legend Biotech Q2 revenue beats estimates on commercial expansion
Aug 10 - Quanterix Q2 revenue rises 34% but cuts 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)